Search Protocols under revision. Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupIndolent LymphomasDiseaseNHL, T-Cell Type, Cutaneous, UnspecifiedSubgroupICD10C84.8MeSHLymphoma, T-Cell, CutaneousSequenceChemotherapyChemo-substanceBortezomibChlorambucilPrednisoloneChemo-substanceBortezomibChlorambucilPrednisoloneChemo-substanceBortezomibChlorambucilPrednisoloneChemo-substanceBortezomibChlorambucilPrednisoloneNo. Substances12 RadiotherapySupportive therapySupportive substanceAciclovirGranisetronSupportive substanceAciclovirGranisetronSupportive substanceAciclovirGranisetronSupportive substanceAciclovirGranisetronNo. Substances2Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationFirst lineSecond lineTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)NeurotoxicityNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorCoors EAZinzani PLDiseaseKutanes T-Zell-Lymphom, Erstlinie, ECOG 0-1Kutanes T-Zell-Lymphom, vortherapiert, ECOG 0-1OriginDepartment of Dermatology, University of Erlangen-Nuremberg, Erlangen, GermanyUniversity of Bologna, Bologna, ItalyProtocols in Revision 2 protocols foundBortezomib 1.3, Cutaneous T-cell Lymphoma (PID2459 V1.0)Chlorambucil 10 / Prednisolone (75/50/25), cutaneous T-cell Lymphoma (PID3095 V1.0)
